期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

2016年美国临床肿瘤学会年会报道:三阴性乳腺癌研究新进展 被引量：7

Updates of triple-negative breast cancer from 2016 American Society of Clinical Oncology
原文传递
导出
摘要 第52届ASCO年会在美国芝加哥盛大召开。本届会议报告了有关三阴性乳腺癌诊疗的重要研究发现和临床试验成果。笔者从流行病学、关键性研究、新药研究等不同方面,对本次年会中三阴性乳腺癌研究的最新进展进行综合报道。 The 52th American Society of Clinical Oncology （ASCO） annual meeting had been held in Chicago, USA. Throughout the meeting, highlights on researches and clinical updates of triple-negative breast cancer （TNBC） had been reported. This paper provided the advancement in epidemiology, practice-changing clinical trials and new drug researches on TNBC in 2016 ASCO annual meeting.
作者 袁芃
机构地区 国家癌症中心中国医学科学院北京协和医学院肿瘤医院特需医疗部
出处 《中华乳腺病杂志（电子版）》 CAS CSCD 2016年第5期264-268,共5页 Chinese Journal of Breast Disease(Electronic Edition)
关键词 乳腺肿瘤 医学肿瘤学 治疗 Breast neoplasms Medical oncology Therapy
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献14

  • 1Rhiem K, Engel C, Engel J, et al. BRCA1/2 mutation prevalence in triple-negative breast cancer patients without family history of breast and ovarian cancer [ J/OL]. J Clin Oncol, 2016, 34 (15 suppl) : 1090 [ 2016-06-10 ]. http://meeting, ascopubs, org/cgi/content/abstract/ 34/15_suppl/1090? sid = 0a5136e3-2664-4077 -b579-a62056883315.
  • 2Vidula N, Yau C, Wolf DM, et al, Androgen receptor (AR) expression in primary breast cancer (BC) : Correlations with clinical characteristics and outcomes [J/OL]. J Clin Oneol, 2016, 34(15 suppl) : 1072 [ 2016-06-10 ]. http://meeting, ascopubs, org/egi/ content/abstract/34/15_ suppl/1072 ? sid = 934241 ec-6fbe-4624-86fd- 58429d5di961.
  • 3Shao ZM, Li JJ, Pang D, et al. Cbesg-10 : Adjuvant eapeeitabine in combination with docetaxel and eyelophosphamide plus epirubiein for triple negative breast cancer [J/OL]. J Clin Oneol, 2016,34 (15 suppl) : 1012 [ 2016-06-10 ]. bttp://meeting, aseopubs, org/egi/ content/abstract/34/15_ suppl/lO12? sid = aae55a8e-fa44.-4164-b3cf- 99ab8678be78.
  • 4Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al. Adjuvant capesitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide ( C ) in the treatment of early breast cancer ( BC ) : 10-year survival results from the randomized FinXX trial [J/OL]. J Clin Oncol, 2016, 34 (15 suppl): 1001 [ 2016-.06-10]. http:// meeting, ascopubs, org/cgi/content/abstract/34/15_suppl/1001? sid= 4966684b-2491-422d-a7e8 -7646c75636d2.
  • 5Joensuu H, Kellokumpu-Lehtinen PL, Huovlnen R, et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial [J]. J Clin Onco1,2012,30( 1 ) : 11-18.
  • 6Yuan P, Du F, Wang JY, et al. Comparison of four cycles epirubicin and cyclophosphamide ( EC ) followed by four cycles docetaxel (T) versus six cycles docetaxel and carboplatin (TP) as adjuvant chemotherapy for women with operable triple negative breast cancer [ J/ OL]. J Clin Oncol, 2016,34 ( 15 suppl) : 1068 [ 2016-06-10 ]. http :// meeting, ascopubs, org/cgi/content/abstract/34/15_suppl/1068? sid = 31 ab5b91-8746-411 d-ba61 -a6e5c55 d49af.
  • 7Takahashi M, Youemori K, Yamamoto H, et al. A phase I / II trial of olapatib in combination with erihulin in patients with advanced or metastatic triple negative breast cancer (TNBC) previously treated with anthracyclines and taxanes: The analyses of efficacy and safety from phase II [J/OL]. J Clin Oncol, 2016,34(15 suppl) : 108012016-06- 10]. http://meeting, ascopubs, org/cgi/content/abstract/34/15 suppl/1080? sid = 67582b01-a5de-45a7-9c81-31 bble6f02a7.
  • 8Brufsky A, Kim SB, Velu TJ, et al. Cobimetinib (C) +paclitaxel (P) as first-line treatment in patients (pts) with advanced triple-negative breast cancer (TNBC) : Updated results and biomarker data from the phase 2 COLET study [ J/OL]. J Clin 0ncol,2016,34( 15 suppl) :1074 [ 2016-06-10 ]. http://meeting, ascopubs, org/egi/eontent/abstraet/ 34/15_suppl/10747 sid = e53 eOfOc-bee2-4446-85 e5 -4b92fl b09916.
  • 9Adams S, Diamond JR, Hamilton EP, et al. Phase Ib trial of atezolizumab in combination with nab-paelitaxel in patients with metastatic triple-negative breast cancer (mTNBC) [ J/OL ]. J Clin Oncol,2016, 34 ( 15 suppl) : 1009 [2016-06-10]. http://meeting. ascopubs, org/cgi/content/abstract/34/15 _ suppl/1009? sid = ea0f16dS-e998-4447-9e14-5al b141 dc71 c.
  • 10Becerra C, Braiteh FS, Spira AI, et al. A phase Ib/II study of cancer sternness inhibitor napabucasin (BB608) combined with weekly paclitaxel in advanced triple negative breast cancer [ J/OL ]. J Clin 0ncol,2016, 34 ( 15 suppl) : 1094 [ 2016-06-10 ]. http://meeting. ascopubs, org/cgi/content/abstract/34/15 _ suppl/10947 sid = 944337 ed-8 c30-4af5 -9bbf-6336622eda04.

同被引文献86

引证文献7

二级引证文献27

中华乳腺病杂志（电子版）
2016年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部